FDA Official Appointment Sparks Agency Crisis
Here’s a breakdown of the key information from the provided text, focusing on the concerns surrounding Dr. Høeg’s appointment at the FDA:
* New FDA Role: Dr. Høeg has been appointed to oversee the FDA office responsible for the safety and effectiveness of all drugs (over-the-counter and prescription) in the US, as well as approving new drugs.
* Concerns about Politicization: There’s important fear within the FDA that Høeg will inject politics into a traditionally science-based office. This could damage the FDA’s credibility as a reliable partner for pharmaceutical companies.
* Potential Impact on Drug Development: Some fear companies may move drug development overseas to countries with more “stable” regulatory environments if they lose trust in the FDA.
* vaccine Skepticism: Høeg recently served on a CDC advisory panel (handpicked by Robert F. Kennedy Jr.) that revised guidance on the hepatitis B vaccine. During the meeting, she questioned the US childhood vaccination schedule, noting the US recommends more vaccines than many other developed nations. She questioned the justification for this difference, particularly given varying risk populations.
* Counterarguments: The American Academy of Pediatrics defends the US vaccine recommendations as being based on “robust evidence” and largely similar to other developed countries, with variations due to local factors.
* Acknowledged Vaccine Effectiveness: Despite her questions, Høeg acknowledged the effectiveness of the measles vaccine, noting the recent outbreak is primarily among the unvaccinated.
In essence, the article highlights concerns that Høeg’s views on vaccines, coupled with her appointment to a powerful position at the FDA, could lead to a shift away from science-based decision-making and potentially harm public health and pharmaceutical innovation in the US.